VALEDIA®

VALBIOTIS announces positive results from the Phase IIA clinical study of VALEDIA®.

Read the press release

TOTUM-63

VALBIOTIS to present novel data about TOTUM-63 and metabolic diseases prevention at the 2019 scientific sessions of the American Diabetes Association.

Read the press release

VALEDIA®

VALBIOTIS succeeds in the industrial production of VALEDIA®, a major scientific innovation for prediabetic people, in collaboration with the Pierre Fabre group.

Read the press release

VALEDIA®

VALBIOTIS obtains the European patent for VALEDIA®.

Read the press release

VALEDIA®

A major scientific innovation for people with prediabetes.

Prediabetes

VALBIOTIS publishes the first prediabetes market data.

Read the press release

1 6

S c r o l l

Products

.01

Pipeline

4 products in clinical development

.02

VALEDIA® – Prediabetes

Prediabetes
• Reduction of the risk of type 2 diabetes
• Positive Phase IIA clinical study

.03

LpD64

Overweight and /or obesity
• Modulation of intestinal microbiota
• Clinical Phase I/II positive

.04

VAL-070

Mild to moderate hypercholesterolemia
• Reduction of blood LDL-cholesterol
• Clinical Phase I/II positive

.05

TOTUM-63 – Non-alcoholic hepatic steatosis

Non-alcoholic hepatic steatosis
• Reduction of steatosis, risk factor for NASH
• Clinical Phase I/II positive

Key figures

Patent families filed

4

All exploitation rights obtained

Employees

> 35

75% in R&D

Listed on the Stock Exchange

2017

Euronext Growth

Our last posts

24.06.2019

Health Tech Investors Day 2019

En savoir plus

07.06.2019

79th scientific sessions of American Diabetes Association

En savoir plus

06.06.2019

Dietecom

En savoir plus

23.05.2019

F2iC / Champeil / Boursier.com

En savoir plus

Voir tous

VALBIOTIS© listed on the Stock Exchange

Investors

Follow us!